A detailed history of Yousif Capital Management, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Yousif Capital Management, LLC holds 48,146 shares of HALO stock, worth $2.33 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
48,146
Previous 54,623 11.86%
Holding current value
$2.33 Million
Previous $2.86 Million 3.71%
% of portfolio
0.03%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$51.3 - $64.42 $332,270 - $417,248
-6,477 Reduced 11.86%
48,146 $2.75 Million
Q2 2024

Jul 31, 2024

SELL
$37.81 - $52.4 $243,836 - $337,927
-6,449 Reduced 10.56%
54,623 $2.86 Million
Q1 2024

Apr 26, 2024

SELL
$33.68 - $41.95 $70,391 - $87,675
-2,090 Reduced 3.31%
61,072 $2.48 Million
Q4 2023

Feb 01, 2024

SELL
$33.32 - $42.1 $30,287 - $38,268
-909 Reduced 1.42%
63,162 $2.33 Million
Q3 2023

Oct 30, 2023

SELL
$36.46 - $44.03 $123,052 - $148,601
-3,375 Reduced 5.0%
64,071 $2.45 Million
Q2 2023

Aug 02, 2023

SELL
$30.28 - $38.74 $125,116 - $160,073
-4,132 Reduced 5.77%
67,446 $2.43 Million
Q1 2023

May 02, 2023

SELL
$32.86 - $55.7 $12,158 - $20,609
-370 Reduced 0.51%
71,578 $2.73 Million
Q4 2022

Jan 09, 2023

BUY
$40.06 - $59.44 $48,512 - $71,981
1,211 Added 1.71%
71,948 $0
Q3 2022

Nov 04, 2022

SELL
$38.53 - $51.78 $258,305 - $347,133
-6,704 Reduced 8.66%
70,737 $2.8 Million
Q2 2022

Aug 01, 2022

BUY
$37.35 - $48.3 $97,483 - $126,062
2,610 Added 3.49%
77,441 $3.41 Million
Q1 2022

May 12, 2022

BUY
$31.97 - $41.06 $94,087 - $120,839
2,943 Added 4.09%
74,831 $2.98 Million
Q4 2021

Jan 31, 2022

BUY
$31.82 - $40.75 $2.29 Million - $2.93 Million
71,888 New
71,888 $2.89 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.75B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Yousif Capital Management, LLC Portfolio

Follow Yousif Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Yousif Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Yousif Capital Management, LLC with notifications on news.